Oct. 27 at 12:57 PM
$AMRN 💰 FDA JUST UNLOCKED A
$5–8B OPPORTUNITY FOR AMRN 🚀 | THE NUMBERS BEHIND THE SHIFT 🧠
The FDA’s fibrate ruling just rewired the lipid market — and Amarin’s latest Corporate Overview 📊 spells out the upside.
🇺🇸 United States:
Over 12M fibrate and 3M EPA+DHA prescriptions are written each year — nearly 15M total from drugs now proven to offer no cardiovascular benefit. With Vascepa priced around
$1K–
$1.2K per patient annually, even a 20 % conversion equals
$3B in new revenue.
🤯 A 30–40 % shift could expand that to
$4.5–
$6B TAM in the U.S. alone.
🌍 Europe:
Roughly 245M fibrate doses are dispensed yearly (~2M patients). Converting just a portion adds another
$1.5–
$2B opportunity.
📈 Takeaway:
The FDA confirmed what the Corporate Overview visual shows 📸 — fibrates ❌ failed event reduction, while Vascepa/Vazkepa ✅ achieved a 25 % RRR across 8,000+ patients.
That’s a
$5–
$8B global gap 🌐 now wide open for Amarin to capture & control in cardio care.
